Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?

Nature Reviews Clinical Oncology

Volumn 9, Issue 9, 2012, Pages 529-541

  Beelen, Karin ^a   Zwart, Wilbert ^a   Linn, Sabine C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLIN D1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; EVEROLIMUS; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL PRACTICE; HORMONAL THERAPY; HUMAN; PATIENT SELECTION; PERSONALIZED MEDICINE; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOCRINE SYSTEM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENETIC MARKERS; HUMANS; PROGNOSIS; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84865698636     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.121     Document Type: Review

References (140)

1. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835-839 (1995).
2. Frasor, J. et al. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562-4574 (2003).
3. McKenna, N. J., Lanz, R. B. & O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20, 321-344 (1999).
4. Xu, J. & Li, Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17, 1681-1692 (2003).
5. Ring, A. & Dowsett, M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643-658 (2004).
6. Smith, C. L. & O'Malley, B. W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
7. Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
8. Smith, I. E. & Dowsett, M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431-2442 (2003).
9. Geisler, J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole-of clinical importance? Br. J. Cancer 104, 1059-1066 (2011).
10. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
11. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
12. Hunter, D. J, Khoury, M. J. & Drazen, J. M. Letting the genome out of the bottle-will we get our wish? N. Engl. J. Med. 358, 105-107 (2008).
13. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 101, 1446-1452 (2009).
14. Luporsi, E. et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res. Treat 132, 895-915 (2012).
15. Coleman, R. E. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat. Rev. Clin. Oncol. 9, 76-78 (2012).
16. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97, 1180-1184 (2005).
17. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
18. Early Breast Cancer Trialists' Collaborative Group, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
19. Holst, F. et al. Estrogen receptor a (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 39, 655-660 (2007).
20. Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111-4119 (2010).
21. Kim, C. et al. Estrogen Receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J. Clin. Oncol. 29, 4160-4167 (2011).
22. Chen, D. et al. Phosphorylation of human estrogen receptor a at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21, 4921-4931 (2002).
23. Michalides, R. et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor a after PKA activation in breast cancer. Cancer Cell 5, 597-605 (2004).
24. Likhite, V. S., Stossi, F., Kim, K., Katzenellenbogen, B. S. & Katzenellenbogen, J. A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20, 3120-3132 (2006).
25. Kok, M. et al. Estrogen receptor-a phosphorylation at serine-118 and tamoxifen response in breast cancer. J. Natl Cancer Inst. 101, 1725-1729 (2009).
26. Murphy, L. et al. Phospho-serine-118 estrogen receptor-a detection in human breast tumors in vivo. Clin. Cancer Res. 10, 1354-1359 (2004).
27. Bergqvist, J. et al. Activated ERK1/2 and phosphorylated oestrogen receptor a are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 42, 1104-1112 (2006).
28. Sarwar, N. et al. Phosphorylation of ERa at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERa phosphorylation in breast cancer progression. Endocr. Relat. Cancer 13, 851-861 (2006).
29. Yamashita, H. et al. Low phosphorylation of estrogen receptor a (ERa) serine 118 and high phosphorylation of ERa serine 167 improve survival in ER-positive breast cancer. Endocr. Relat. Cancer 15, 755-763 (2008).
30. Campbell, R. A. et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor a: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817-9824 (2001).
31. Joel, P. B. et al. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell Biol. 18, 1978-1984 (1998).
32. Jiang, J. et al. Phosphorylation of estrogen receptor-a at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 13, 5769-5776 (2007).
33. Motomura, K. et al. Expression of estrogen receptor ß and phosphorylation of estrogen receptor a serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology 79, 55-61 (2010).
34. Yamashita, H. et al. Phosphorylation of estrogen receptor a serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 7, R753-R764 (2005).
35. Zwart, W. et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERa towards co-activator SRC-1. EMBO J. 26, 3534-3544 (2007).
36. Holm, C. et al. Phosphorylation of the oestrogen receptor a at serine 305 and prediction of tamoxifen resistance in breast cancer. J. Pathol. 217, 372-379 (2009).
37. Kok, M. et al. PKA-induced phosphorylation of ERa at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res. Treat 125, 1-12 (2011).
38. Bostner, J., Skoog, L., Fornander, T., Nordenskjöld, B. & Stål, O. Estrogen receptor-a phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin. Cancer Res. 16, 1624-1633 (2010).
39. Wu, X. et al. Estrogen receptor-ß sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 13, R27 (2011).
40. Hartman, J., Ström, A. & Gustafsson, J. A. Estrogen receptor ß in breast cancer-diagnostic and therapeutic implications. Steroids 74, 635-641 (2009).
41. Horwitz, K. B. & McGuire, W. L. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J. Biol. Chem. 253, 8185-8191 (1978).
42. Nardulli, A. M., Greene, G. L., O'Malley, B. W. & Katzenellenbogen, B. S. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology 122, 935-944 (1988).
43. Osborne, C. K., Schiff, R., Arpino, G., Lee, A. S. & Hilsenbeck, V. G. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14, 458-465 (2005).
44. Zafrani, B. et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37, 536-545 (2000).
45. Stendahl, M. et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin. Cancer Res. 12, 4614-4618 (2006).
46. Redmond, A. M. et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin. Cancer Res. 15, 2098-2106 (2009).
47. Myers, E. et al. Inverse relationship between ER-ß and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br. J. Cancer 91, 1687-1693 (2004).
48. Al-azawi, D. et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 27, 3021-3031 (2008).
49. Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353-361 (2003).
50. Alkner, S. et al. AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann. Oncol. 21, 238-244 (2010).
51. Kirkegaard, T. et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 13, 1405-1411 (2007).
52. Knowlden, J. M. et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044 (2003).
53. Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926-935 (2004).
54. Zhang, Y. et al. Elevated insulin-like growth factor 1 receptor signaling induces anti-estrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 13, R52 (2011).
55. Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094 (2010).
56. Giltnane, J. M. et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J. Clin. Oncol. 25, 3007-3014 (2007).
57. Rydén, L. et al. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res. Treat 109, 351-357 (2008).
58. Love, R. R. et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J. Clin. Oncol. 21, 453-457 (2003).
59. Dowsett, M. et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 17, 818-826 (2006).
60. Dowsett, M. et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 561, 8452-8458 (2001).
61. Ellis, M. J. et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19, 3808-3816 (2001).
62. Ellis, M. J. et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63, 6523-6531 (2003).
63. Smith, I. E. et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23, 5108-5116 (2005).
64. Bartlett, J. M. S. et al. Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the TEAM pathology sub-study [abstract]. Cancer Res. 70(Suppl. 2), 2-4 (2010).
65. Dowsett, M. et al. Predictive algorithms for adjuvant therapy: TransATAC. Steroids 76, 777-780 (2011).
66. Fagan, D. H. & Yee, D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 423-429 (2008).
67. Henriksen, K. L. et al. An ER activity profile including, ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 48, 522-531 (2009).
68. Law, J. H. et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238-10246 (2008).
69. Isakoff, S. J. et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 165, 10992-11000 (2005).
70. Li, S. Y., Rong, M., Grieu, F. & Iacopetta, B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat 96, 91-95 (2006).
71. Maruyama, N. et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin. Cancer Res. 13, 408-414 (2007).
72. Saal, L. H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559 (2005).
73. Pérez-Tenorio, G. et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13, 3577-3584 (2007).
74. O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
75. Barbareschi, M. et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin. Cancer Res. 13, 6064-6069 (2007).
76. Ellis, M. J. et al. Phosphatidyl-inositol-3-kinase a catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res. Treat 119, 379-390 (2010).
77. Loi, S. et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl Acad. Sci. USA 107, 10208-10213 (2010).
78. Folgiero, V. et al. Induction of ErbB-3 expression by a6ß4 integrin contributes to tamoxifen resistance in ERß1-negative breast carcinomas. PLoS ONE 3, e1592 (2008).
79. Generali, D. et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin. Cancer Res. 14, 2673-2680 (2008).
80. Tokunaga, E. et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur. J. Cancer 42, 629-635 (2006).
81. Yamashita, H. et al. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci. 100, 2028-2033 (2009).
82. Kim, E. K. et al. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res. Treat 126, 93-99 (2011).
83. McGlynn, L. M. et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin. Cancer Res. 15, 1487-1495 (2009).
84. Baker, A. F. et al. Stability of phosphoprotein as a biological marker of tumor signaling. Clin. Cancer Res. 11, 4338-4340 (2005).
85. Miller, T. W. et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. 869, 4192-4201 (2009).
86. Ong, C. C. et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2, 491-496 (2011).
87. Bostner, J. et al. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26, 6997-7005 (2007).
88. Holm, C. et al. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J. Natl Cancer Inst. 98, 671-680 (2006).
89. Lundgren, K., Holm, K., Nordenskjöld, K., Borg, A. & Landberg, G. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 10, R81 (2008).
90. Jirström, K. et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 65, 8009-8016 (2005).
91. Rudas, M. et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin. Cancer Res. 14, 1767-1774 (2008).
92. Michalides, R. et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer 86, 402-408 (2002).
93. Akli, S. et al. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin. Cancer Res. 16, 1179-1190 (2010).
94. Span, P. N., Tjan-Heijnen, V. C., Manders, P., Beex, L. V. & Sweep, C. G. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22, 4898-4904 (2003).
95. Stendahl, M. et al. p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int. J. Cancer 127, 2851-2858 (2010).
96. Cheang, M. C. U. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736-750 (2009).
97. Jirström, K. et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J. Clin. Pathol. 58, 1135-1142 (2005).
98. Viale, G. et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J. Clin. Oncol. 26, 5569-5575 (2008).
99. Viale, G. et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann. Oncol. 22, 2201-2207 (2011).
100. Bago-Horvath, Z. et al. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin. Cancer Res. 17, 7828-7834 (2011).
101. Ellis, M. J. et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl Cancer Inst. 100, 1380-1388 (2008).
102. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
103. Jerevall, P. L. et al. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res. 12, R53 (2010).
104. Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
105. Goetz, M. P. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat 101, 113-121 (2007).
106. Wu, X. et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res. 69, 1722-1727 (2009).
107. Dezentjé, V. O., Guchelaar, H. J., Nortier, J. W., van de Velde, C. J. & Gelderblom, H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin. Cancer Res. 15, 15-21 (2009).
108. Seruga, B. & Amir, E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res. Treat 122, 609-617 (2010).
109. Rae, J. M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl Cancer Inst. 104, 452-460 (2012).
110. Regan, M. M. et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J. Natl Cancer Inst. 104, 441-451 (2012).
111. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30-39 (2005).
112. Madlensky, L. et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89, 718-725 (2011).
113. Kallström, A. C. et al. 17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. Eur. J. Cancer 46, 892-900 (2010).
114. Jansson, A. et al. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin. Cancer Res. 15, 3610-3616 (2009).
115. Wang, L. et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 70, 319-328 (2010).
116. Colomer, R. et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin. Cancer Res. 14, 811-816 (2008).
117. Garcia-Casado, Z. et al. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 10, 36 (2010).
118. Johnston, S. R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 1979-1987 (2010).
119. Di Cosimo, S. & Baselga, J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat. Rev. Clin. Oncol. 7, 139-147 (2010).
120. Kaufman, B. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 27, 5529-5537 (2009).
121. Johnston, S. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27, 5538-5546 (2009).
122. Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283 (2011).
123. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
124. Baselga, J. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2630-2637 (2009).
125. Chow, L. et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract]. Breast Cancer Res. Treat 100, a6091 (2006).
126. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2011).
127. Bachelot, T. et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2011.39.0708
128. Powell, E., Wang, Y., Shapiro, D. J. & Xu, W. Differential requirements of Hsp90 and DNA for the formation of estrogen receptor homodimers and heterodimers. J. Biol. Chem. 285, 16125-16134 (2010).
129. Safe, S. & Kim, K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 41, 263-275 (2008).
130. Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494 (1995).
131. Levin, E. R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 20, 477-482 (2009).
132. Sheri, A., Martin, L. A. & Johnston, S. Targeting endocrine resistance: is there a role for mTOR inhibition? Clin. Breast Cancer 10(Suppl. 3), 79-85 (2010).
133. Simpson, L. & Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res. 264, 29-41 (2001).
134. Santen, R. J. et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80, 239-256 (2002).
135. Christov, K. et al. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res. Treat 77, 253-264 (2003).
136. Urruticoechea, A. et al. Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. Breast Cancer Res. Treat 109, 463-470 (2008).
137. Thiantanawat, A., Long, B. J. & Brodie, A. M. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 63, 8037-8050 (2003).
138. Planas-Silva, M. D. & Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell Biol. 17, 4059-4069 (1997).
139. Doisneau-Sixou, S. F., Cestac, P., Faye, J. C., Favre, G. & Sutherland, R. L. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int. J. Cancer 106, 789-798 (2003).
140. Buyse, M., Sargent, D. J., Grothey, A. Matheson, A. & de Gramont, A. Biomarkers and surrogate end points-the challenge of statistical validation. Nat. Rev. Clin. Oncol. 7, 309-317 (2010).